Melanocyte differentiation antigen RAB38/NY-MEL-1 induces frequent antibody responses exclusively in melanoma patients (original) (raw)
Editorial: Advancements in Molecular Diagnosis and Treatment of Melanoma
Giuseppe Palmieri
Frontiers in Oncology
View PDFchevron_right
Prognostic value of quantitative immune alterations in melanoma patients
A. Tres
Oncología (Barcelona), 2006
View PDFchevron_right
Melanoma and immunotherapy bridge 2015
Angel Rivera
Journal of Translational Medicine, 2016
View PDFchevron_right
Outcomes of Immunosuppressed Patients Who Develop Melanoma: A Population-Based Propensity-Matched Cohort Study
Janice Austin
Annals of Surgical Oncology, 2020
View PDFchevron_right
Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers
Olga Vornicova
International Journal of Molecular Sciences, 2023
View PDFchevron_right
Multiple mechanisms of immune evasion can coexist in melanoma tumor cell lines derived from the same patient
Luis Real
Cancer Immunology, Immunotherapy, 2001
View PDFchevron_right
Identification of new genes associated with melanoma
Thomas Stempfl
Experimental Dermatology, 2011
View PDFchevron_right
Genes and signaling pathways affecting the pathogenesis of melanoma
Bridget Varughese
Postdoc Journal, 2013
View PDFchevron_right
Immunologic escape and angiogenesis in human malignant melanoma
Pedro Redondo
Journal of the American Academy of Dermatology, 2003
View PDFchevron_right
Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies
Charles E. Terry
Cancer Immunology Research, 2015
View PDFchevron_right
Cross-presentation of cutaneous melanoma antigen by migratory XCR1+CD103−and XCR1+CD103+dendritic cells
Rachael Zemek
OncoImmunology, 2015
View PDFchevron_right
Preferentially Expressed Antigen in Melanoma (PRAME) Expression in Malignant, but Not Benign, Peripheral Nerve Sheath Tumors
Divya Srihari
Journal of Neuropathology & Experimental Neurology, 2020
View PDFchevron_right
Tumor screening and biology in malignant melanomas
Salvador J Diaz-Cano
2000
View PDFchevron_right
UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma
Lea Eisenbach
Cell, 2019
View PDFchevron_right
Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts
Genny Del Zotto
Journal of Translational Medicine, 2018
View PDFchevron_right
Altered molecular pathways in melanocytic lesions
Maria Scatolini
International Journal of Cancer, 2009
View PDFchevron_right
Melanin Pigments and Melanosomal Proteins as Differentiation Markers Unique to Normal and Neoplastic Melanocytes
K. Jimbow
Journal of Investigative Dermatology, 1993
View PDFchevron_right
Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012”
Ena Wang
Journal of Translational Medicine, 2013
View PDFchevron_right
Meeting report: consensus from the first and second Global Workshops in Melanoma November 19-20, 2008
Wolfram Samlowski, Sancy Leachman
Pigment Cell & Melanoma Research, 2009
View PDFchevron_right
Clinical status of diagnosis and therapy of malignant melanoma
Alessandro Testori
International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology, 1989
View PDFchevron_right
Immunotherapy Outcomes in Advanced Melanoma in Relation to Age
Issam Makhoul
The Permanente Journal, 2020
View PDFchevron_right
Vaccination of Stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells
Cristina SANTANTONIO
Cancer Immunology, Immunotherapy, 2002
View PDFchevron_right
Analysis of therapeutic and immunologic effects of R24 anti‐GD3 monoclonal antibody in 37 patients with metastatic melanoma
Roger Day
Cancer, 2000
View PDFchevron_right
Molecular characterization of the melanocyte lineage-specific antigen gp100
Annemiek Boer
Journal of biological …, 1994
View PDFchevron_right
Expression of the tumor antigens NY-ESO-1, tyrosinase, MAGE-A3, and TPTE in pediatric and adult melanoma: a retrospective case control study
Isabel Büttel
Virchows Archiv, 2024
View PDFchevron_right
Radioimmunoimaging In Malignant Melanoma With 111In-Labeled Monoclonal Antibody 96.5
Lamk Lamki
Cancer research, 1985
View PDFchevron_right
Cell-based vaccination against melanoma – background, preliminary results, and perspective
Dirk Schadendorf
Journal of Molecular Medicine, 1999
View PDFchevron_right
In Vivo Melanoma Cell Morphology Reflects Molecular Signature and Tumor Aggressiveness
Roberta Lotti
Journal of Investigative Dermatology, 2022
View PDFchevron_right
Melanocortin 1 Receptor Is Expressed by Uveal Malignant Melanoma and Can Be Considered a New Target for Diagnosis and Immunotherapy
Marcos Ramírez
Investigative Ophthalmology & Visual Science, 2007
View PDFchevron_right
Vitiligo-like leukoderma as an indicator of clinical response to immune checkpoint inhibitors in late-stage melanoma patients
Cristina Fortes
Journal of Cancer Research and Clinical Oncology, 2021
View PDFchevron_right
Malignant Melanoma in the 21st Century, Part 1: Epidemiology, Risk Factors, Screening, Prevention, and Diagnosis
Ravi Dama
Mayo Clinic Proceedings, 2007
View PDFchevron_right
Specific killing of human melanoma cells by 125I-labeled 9.2.27 monoclonal antibody
George Morstyn
Cancer Research, 1985
View PDFchevron_right
Increased expression of stem cell markers in malignant melanoma
Hong Wu
Modern Pathology, 2006
View PDFchevron_right
Spontaneous CD8 T Cell Responses against the Melanocyte Differentiation Antigen RAB38/NY-MEL-1 in Melanoma Patients
asma gati
The Journal of …, 2006
View PDFchevron_right
Medical Immunosuppression and Outcomes in Cutaneous Melanoma: A Population-Based Cohort Study
Janice Austin
Annals of Surgical Oncology, 2020
View PDFchevron_right